An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)
About the study
Optional open label, roll over extension study to investigate the efficacy and safety of secukinumab treatment in Juvenile Idiopathic Arthritis (JIA) subtypes of Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA).
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Patient must have participated in core study CAIN457F2304, and must have completed the entire treatment period up to and including Week 104.
- Patients must be deemed by the investigator to benefit from continued secukinumab therapy.
EXCLUSION CRITERIA
Exclusion Criteria:
- Plans for administration of live vaccines during the extension study period.
- Any patient taking other concomitant biologic immunomodulating agent(s) except secukinumab.
- Any patient who is deemed not to be benefiting from the study treatment based upon lack of improvement or worsening of their symptoms.
All other protocol related inclusion/exclusion criteria will apply.
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Juvenile Psoriatic Arthritis,Enthesitis Related Arthritis
Age (in years)
2+
Phase
Phase 3
Participants needed
55
Est. Completion Date
Nov 27, 2024
Treatment type
Interventional
Sponsor
Novartis
ClinicalTrials.gov identifier
NCT03769168
Study number
CAIN457F2304E1
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?